Breast Cancer, HER2 and Pfizer

ER+ and PR+ Breast Cancer: Key Statistics and Molecular Insights
ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements.
Pfizer-Arvinas' breast cancer treatment shows mixed results in late-stage study
Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of patients in a late-stage trial, sending the Connecticut-based biotech's shares down 36% before the bell.
First Patients Enrolled in Trial on Anti-HER2 Therapy in HER2+ Breast Cancer
The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ breast cancer using circulating tumor DNA.
Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients
Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it was only able to extend progression-free survival (PFS) in certain patients in a Phase III trial.
Pfizer-Arvinas' breast cancer treatment cuts progression for some patients in study
An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients lived without the disease worsening, but failed to achieve statistically significant results in others in a late-stage study.
Pfizer, Arvinas post mixed late-stage trial results for breast cancer therapy (update)
Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed initial results from a Phase 3 trial for the protein degrader on Tuesday.
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug
Arvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast cancer drug.
Mom Faked Cancer to Swindle Partner Out of $32,000 for 'Treatment,' Spent Money on Breast Surgery: Reports
A mother faked cancer to swindle her partner out of $32,000 for 'treatment' when she was actually spending the money on ...
Inflammatory Breast Cancer (IBC): A Comprehensive Guide to Symptoms, Treatment, and Prevention
IBC is a rare, aggressive breast cancer with higher rates in younger women and those of African descent, requiring a ...
PharmExec5h
Phase III Trial Data Show Vepdegestrant Produces Encouraging Outcomes in ER+/HER2- Advanced or Metastatic Breast Cancer
Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...
Breast cancer deaths rates for older women have been declining for years. Not anymore
Breast cancer is the second leading cause of cancer deaths in women in the U.S., killing more than 42,000 last year ...
Medscape2d
Chemotherapy Linked to Long-Lasting Health Decline in Breast Cancer Survivors
Women with breast cancer who receive chemotherapy experienced a lasting decline in physical health, a new study found.
The Gazette15h
Iowa bill would expand coverage for breast cancer screening
About a quarter of Iowans would no longer pay co-pays and deductibles for supplemental and diagnostic breast exams under ...
BioPharma Dive1d
Arvinas gets positive breast cancer data, but finds differentiation a hard sell
Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...
The Indiana Gazette2d
How to approach work after a breast cancer diagnosis
A breast cancer diagnosis affects every facet of a woman’s life. While women and their families must prioritize treatment, a ...
Triple-Negative Breast Cancer (TNBC): Understanding Diagnosis and Treatment
TNBC, aggressive and lacking key receptors, complicates treatment, impacting prognosis and requiring specialized approaches.